EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Insulin‐Like Growth Factor 2 mRNA ‐Binding Protein 2 ( IGF2BP2 ) Promotes Castration‐Resistant Prostate Cancer Progression by Regulating AR ‐ V7 mRNA Stability

Taruna Saini, Devesh Srivastava, Rajnikant Raut, Parul Mishra, Ashish Misra iD

Cancer Reports · 2025

DOI: 10.1002/cnr2.70096 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Reports, 2025. Verfasst von Taruna Saini und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Indian Institute of Technology Hyderabad, Kandi, Sangareddy, India. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, RNA-Binding Proteins, Receptors, Androgen, RNA Stability. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India, Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The emergence of constitutively active androgen receptor (AR) splice variant AR‐V7 poses a formidable challenge in treating prostate cancer, as it lacks the ligand binding region targeted by androgen‐deprivation therapies such as enzalutamide and abiraterone. AR‐V7 is critical for castration‐resistant prostate cancer (CRPC) development and progression; however, the molecular mechanisms regulating its expression and biological function remain poorly understood. Here, we investigate the role of IGF2BP2 in regulating AR‐V7 expression and CRPC progression.

Methods

To determine the clinical relevance of IGF2BP2 in CRPC, we analyzed the mRNA expression data for prostate cancer patients available in the Genomic Data Commons (GDC) Data Portal and cBioPortal. Next to investigate the role of IGF2BP2 in regulating AR‐V7 expression and enzalutamide resistance, we performed shRNA‐mediated IGF2BP2 knockdown and overexpression experiments followed by qRT‐PCR, immunoblot, colony‐formation, and MTT assays. Finally, we performed RIP‐qPCR, actinomycin‐D, and IGF2BP2 domain‐deletion analysis to study the mechanism by which IGF2BP2 regulates AR‐V7 stability, expression, and enzalutamide resistance in CRPC cells.

Results

Our analysis revealed that IGF2BP2 is upregulated in CRPC patients and its expression positively correlates with increasing Gleason score in patients with CRPC. We demonstrate that IGF2BP2 silencing leads to downregulation of AR‐V7 and its downstream target genes without affecting AR levels. Additionally, IGF2BP2 knockdown also enhances the sensitivity of CRPC cells to enzalutamide while overexpression increases AR‐V7 expression and confers increased resistance to enzalutamide. Mechanistically, our experiments demonstrate that IGF2BP2 binds to the intronic splicing enhancer (ISE) region of AR‐V7, thereby enhancing its mRNA stability. Furthermore, our domain‐deletion analysis pinpoints the role of KH3 and KH4 domains of IGF2BP2 in regulating AR‐V7 stability and enzalutamide resistance.

Conclusions

Taken together, our findings suggest that IGF2BP2 plays a critical role in regulating AR‐V7 expression and stability, offering a novel target for developing therapeutic interventions for CRPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantRNA-Binding ProteinsReceptors, AndrogenRNA StabilityHumansMaleDrug Resistance, NeoplasmBenzamidesDisease ProgressionNitrilesGene Expression Regulation, NeoplasticPhenylthiohydantoinCell Line, TumorRNA, MessengerInsulin-Like Peptides

Stichwörter der Autor:innen

AR‐V7IGF2BP2RNA‐binding proteinsandrogen receptorcastration‐resistant prostate cancer

Substanzen

RNA-Binding ProteinsReceptors, AndrogenAR protein, humanBenzamidesIGF2BP2 protein, humanenzalutamideNitrilesPhenylthiohydantoinRNA, MessengerInsulin-Like Peptides

Autor:innen und Institutionen

  • Department of Biotechnology, Indian Institute of Technology Hyderabad, Kandi, Sangareddy, India.
  • Department of Animal Biology, School of Life Sciences, University of Hyderabad, Hyderabad, India.

ORCID-Profile: Ashish Misra

Förderung

  • Department of Biotechnology, Ministry of Science and Technology, India
  • Indian Council of Medical Research

Zitieren

APA

Saini, T., Srivastava, D., Raut, R., Mishra, P., & Misra, A. (2025). Insulin‐Like Growth Factor 2 mRNA ‐Binding Protein 2 ( IGF2BP2 ) Promotes Castration‐Resistant Prostate Cancer Progression by Regulating AR ‐ V7 mRNA Stability. Cancer Reports. https://doi.org/10.1002/cnr2.70096

Vancouver

Saini T, Srivastava D, Raut R, Mishra P, Misra A. Insulin‐Like Growth Factor 2 mRNA ‐Binding Protein 2 ( IGF2BP2 ) Promotes Castration‐Resistant Prostate Cancer Progression by Regulating AR ‐ V7 mRNA Stability. Cancer Reports. 2025. doi:10.1002/cnr2.70096

BibTeX
@article{Saini2025,
  author = {Saini, Taruna and Srivastava, Devesh and Raut, Rajnikant and Mishra, Parul and Misra, Ashish},
  title = {Insulin‐Like Growth Factor 2 mRNA ‐Binding Protein 2 ( IGF2BP2 ) Promotes Castration‐Resistant Prostate Cancer Progression by Regulating AR ‐ V7 mRNA Stability},
  journal = {Cancer Reports},
  year = {2025},
  doi = {10.1002/cnr2.70096}
}
Kostenlos starten →